Pharvaris announces Dr. Anne Marie de Jonge Schuermans to its Board of Directors

– SWITZERLAND, Zug –  Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema and other bradykinin-B2-receptor-mediated indications, today announced the appointment of Dr. Anne Marie de Jonge Schuermans (Ph.D.) to its board of directors, to replace Rémi Droller, who has stepped down from the board effective Dec. 22, 2021.

“Anne Marie is a tremendous addition to our board. She has a proven track record of developing processes and systems in manufacturing operations and overseeing CMC strategies and commercial launches. Her expertise will be invaluable as Pharvaris prepares for commercialization in anticipation of its clinical data read out in the next year from Phase 2 clinical studies in prophylactic and on-demand treatment of HAE. We look forward to working with her as we execute on our plans to bring novel oral therapy options to HAE patients,” said Board Chair, Dr. David Meeker.

Berndt Modig, co-founder and CEO added, “We are thrilled to add Anne Marie’s breadth of experience to our board. We also thank Rémi Droller for his commitment to Pharvaris and the guidance he has provided while serving on our board for the past five years. We appreciate the strategic insight Rémi has provided to Pharvaris from our Series A funding through to today.”

About Dr. Anne Marie de Jonge Schuermans

Dr. de Jonge Schuermans is an Executive Committee member and Senior Vice President at Swedish Orphan Biovitrum (Sobi) where she is responsible for all Technical Operations encompassing CMC development, manufacturing, sourcing, supply chain, and quality for a broad range of commercial and development products in rare diseases. Before joining Sobi, she held roles as VP Global Manufacturing Operations and VP Global Supply Chain Operations & Partnerships at Biogen. Before that, she spent almost 15 years in Novartis in various technical roles. Throughout her career, she has built up experience in biotech, pharma, medical device, and consumer health for a wide range of technologies in multiple territories and regulations.

About Pharvaris

Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The Company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE.

For more information: https://pharvaris.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team